KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacira BioSciences (PCRX) Treasury Shares (2016 - 2025)

Historic Treasury Shares for Pacira BioSciences (PCRX) over the last 15 years, with Q3 2025 value amounting to $4.8 million.

  • Pacira BioSciences' Treasury Shares rose 46981.43% to $4.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.8 million, marking a year-over-year increase of 46981.43%. This contributed to the annual value of $837240.0 for FY2024, which is N/A changed from last year.
  • Pacira BioSciences' Treasury Shares amounted to $125.5 million in Q3 2025, which was up 39975.32% from $75.5 million recorded in Q2 2025.
  • In the past 5 years, Pacira BioSciences' Treasury Shares registered a high of $4.8 million during Q3 2025, and its lowest value of $837000.0 during Q2 2024.
  • In the last 5 years, Pacira BioSciences' Treasury Shares had a median value of $981953.0 in 2022 and averaged $1.4 million.
  • Examining YoY changes over the last 5 years, Pacira BioSciences' Treasury Shares showed a top increase of 39975.32% in 2025 and a maximum decrease of 20060.51% in 2025.
  • Quarter analysis of 2 years shows Pacira BioSciences' Treasury Shares stood at $25.1 million in 2024, then skyrocketed by 399.75% to $125.5 million in 2025.
  • Its Treasury Shares was $4.8 million in Q3 2025, compared to $2.8 million in Q2 2025 and $837000.0 in Q1 2025.